This content was published on May 04, 2022 – 12:43
New York, May 4 (EFE) .- The American pharmaceutical company Moderna earned between January and March 3,657 million dollars, almost three times more than the 1,221 million achieved in the same quarter of 2021, thanks to the sales of its vaccine against covid -19, which skyrocketed to $5.925 million.
The company also tripled its revenue in the first quarter, which reached 6,066 million dollars, compared to 1,937 achieved in the same period last year.
Likewise, its earnings per share between January and March also soared to $8.58, compared to the first quarter of 2021, when they stood at $2.84.
The company also reiterated that its sales forecasts for the covid-19 vaccine for the year as a whole are 21,000 million dollars.
“Moderna’s team had a strong first quarter performance and I am grateful for the progress our team continues to make as we advance our mRNA drug portfolio,” said CEO Stéphane Bancel.
Bancel highlighted that the company continues to work on the manufacture of several products, such as the double vaccine for covid and flu, and to treat other respiratory conditions.
Last week, Moderna applied to US and European Union health authorities for emergency authorization of its covid-19 vaccine for children between 6 months and 6 years of age.
This Wednesday, after disclosing its accounts, the company’s shares soared up to 6.11% in electronic operations prior to the opening of the New York Stock Exchange. EFE
jfu / si
© EFE 2022. The redistribution and rebroadcasting of all or part of the contents of Efe’s services is expressly prohibited, without the prior and express consent of Agencia EFE SA
–
